FDA approves new sBLA for Gazyva plus chlorambucil

FDA approves new sBLA for Gazyva plus chlorambucil
FDA approves new sBLA for Gazyva plus chlorambucil

Genentech announced that the Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL)

The sBLA includes complete response (CR) and minimal residual disease (MRD) data from Stage 2 of the Phase 3 CLL11 study that compared Gazyva plus chlorambucil vs. Rituxan (rituximab) plus chlorambucil in a head-to-head study; overall survival (OS) data from Stage 1 of the study comparing Gazyva plus chlorambucil vs. chlorambucil alone was also included. Treatment with Gazyva plus chlorambucil showed significant improvements across multiple study endpoints vs. Rituxan plus chlorambucil. 

Key study data points added to the label include: 

  • Gazyva plus chlorambucil resulted in a longer progression-free survival (PFS) than Rituxan plus chlorambucil (median PFS: 26.7 months vs. 14.9 months, respectively, HR 0.42, 95% CI 0.33–0.54, P<0.0001).
  • Gazyva plus chlorambucil nearly tripled the number of people showing no evidence of disease (CR) compared to Rituxan plus chlorambucil (26.1% vs. 8.8%, respectively).
  • Of the people who achieved a complete response with or without complete recovery from abnormal blood cell counts, 19% (18/94) of people in the Gazyva arm vs. 6% (2/34) of people in the Rituxan arm were MRD negative in the bone marrow, and 41% (39/94) of people in the Gazyva arm vs. 12% (4/34) people in the Rituxan arm were MRD negative in the peripheral blood.
  • Data from the Stage 1 of the CLL11 study showed that at nearly 2 years, the rate of death was 9% (22/238) for people who received Gazyva plus chlorambucil vs. 20% (24/118) for those who received chlorambucil alone (HR 0.41, 95% CI 0.23–0.74). 
 For more information call (888) 835-2555 or visit Gazyva.com.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs